These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 9563865)

  • 1. Effects of propofol on ipecacuanha-induced nausea and vomiting.
    Hammas B; Hvarfner A; Thörn SE; Wattwil M
    Acta Anaesthesiol Scand; 1998 Apr; 42(4):447-51. PubMed ID: 9563865
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Betamethasone does not prevent nausea and vomiting induced by ipecacuanha.
    Axelsson P; Thörn SE; Wattwil M
    Acta Anaesthesiol Scand; 2004 Nov; 48(10):1283-6. PubMed ID: 15504189
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of lerisetron, a new 5-HT3 receptor antagonist, on ipecacuanha-induced emesis in healthy volunteers.
    Cooper M; Sologuren A; Valiente R; Smith J
    Arzneimittelforschung; 2002; 52(9):689-94. PubMed ID: 12404884
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 5-HT3 receptors are not involved in conditioned taste aversions induced by 5-hydroxytryptamine, ipecacuanha or cisplatin.
    Rudd JA; Ngan MP; Wai MK
    Eur J Pharmacol; 1998 Jul; 352(2-3):143-9. PubMed ID: 9716348
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 5-HT3 receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting. A comparison of their pharmacology and clinical efficacy.
    Gregory RE; Ettinger DS
    Drugs; 1998 Feb; 55(2):173-89. PubMed ID: 9506240
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ondansetron reduces nausea induced by gastroduodenal stimulation without changing gastric motility.
    Feinle C; Read NW
    Am J Physiol; 1996 Oct; 271(4 Pt 1):G591-7. PubMed ID: 8897877
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [An outline of 5-HT3 receptor antagonists (1)--In pharmacological actions].
    Tsukagoshi S; Ohta J; Taguchi T
    Gan To Kagaku Ryoho; 1993 Nov; 20(14):2108-14. PubMed ID: 8239673
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Volunteer models for predicting antiemetic activity of 5-HT3-receptor antagonists.
    Minton NA
    Br J Clin Pharmacol; 1994 Jun; 37(6):525-30. PubMed ID: 7917768
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ipecacuanha-induced emesis: a human model for testing antiemetic drug activity.
    Minton N; Swift R; Lawlor C; Mant T; Henry J
    Clin Pharmacol Ther; 1993 Jul; 54(1):53-7. PubMed ID: 8101150
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Studies for the emetic mechanisms of ipecac syrup (TJN-119) and its active components in ferrets: involvement of 5-hydroxytryptamine receptors.
    Hasegawa M; Sasaki T; Sadakane K; Tabuchi M; Takeda Y; Kimura M; Fujii Y
    Jpn J Pharmacol; 2002 Jun; 89(2):113-9. PubMed ID: 12120752
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-emetic effect of ondansetron and granisetron after exposure to mixed neutron and gamma irradiation.
    Martin C; Roman V; Agay D; Fatôme M
    Radiat Res; 1998 Jun; 149(6):631-6. PubMed ID: 9611102
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ondansetron inhibits the analgesic effects of tramadol: a possible 5-HT(3) spinal receptor involvement in acute pain in humans.
    Arcioni R; della Rocca M; Romanò S; Romano R; Pietropaoli P; Gasparetto A
    Anesth Analg; 2002 Jun; 94(6):1553-7, table of contents. PubMed ID: 12032025
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiemetic prophylaxis for office-based surgery: are the 5-HT3 receptor antagonists beneficial?
    Tang J; Chen X; White PF; Wender RH; Ma H; Sloninsky A; Naruse R; Kariger R; Webb T; Zaentz A
    Anesthesiology; 2003 Feb; 98(2):293-8. PubMed ID: 12552184
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacology and preclinical antiemetic properties of ondansetron.
    Tyers MB
    Semin Oncol; 1992 Aug; 19(4 Suppl 10):1-8. PubMed ID: 1387245
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of serotonin3 receptor blockade on the psychobiological response to intravenous clomipramine in healthy human subjects.
    Leatherman ME; Bebchuk JM; Ekstrom RD; Heine AD; Carson SW; Golden RN
    Biol Psychiatry; 1999 Jan; 45(2):238-40. PubMed ID: 9951573
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 5-HT3-receptor antagonists in the control of delayed-onset emesis.
    Gridelli C
    Anticancer Res; 2003; 23(3C):2773-82. PubMed ID: 12926112
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Ondansetron: a specific 5-HT3 serotonin receptor inhibitor, a new antiemetic in oncology].
    d'Allens H; Aubert B; Bons J; Pappo M
    Bull Cancer; 1991; 78(12):1139-46. PubMed ID: 1838490
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A population pharmacokinetic-pharmacodynamic analysis of repeated measures time-to-event pharmacodynamic responses: the antiemetic effect of ondansetron.
    Cox EH; Veyrat-Follet C; Beal SL; Fuseau E; Kenkare S; Sheiner LB
    J Pharmacokinet Biopharm; 1999 Dec; 27(6):625-44. PubMed ID: 11153449
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The broad-spectrum anti-emetic activity of AS-8112, a novel dopamine D2, D3 and 5-HT3 receptors antagonist.
    Yoshikawa T; Yoshida N; Oka M
    Br J Pharmacol; 2001 May; 133(2):253-60. PubMed ID: 11350861
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Possible involvement of 5-HT4 receptors, in addition to 5-HT3 receptors, in the emesis induced by high-dose cisplatin in Suncus murinus.
    Horikoshi K; Yokoyama T; Kishibayashi N; Ohmori K; Ishii A; Karasawa A
    Jpn J Pharmacol; 2001 Jan; 85(1):70-4. PubMed ID: 11243577
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.